Indications for: DHIVY

Treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Adult Dosage:

Individualize. Initially one tab (25mg/100mg) 3 times daily; may increase by up to one whole tab every day or every other day as needed; max 8 whole tabs daily.

Children Dosage:

Not established.

DHIVY Contraindications:

During or within 14 days of nonselective MAOIs (eg, phenelzine, linezolid, tranylcypromine).

Boxed Warning:

DHIVY Warnings/Precautions:

Sleep disorders; consider discontinuing if significant daytime sleepiness occurs. History of MI with residual arrhythmias; monitor cardiac function. Risk of hallucinations and psychosis. Major psychotic disorder: not recommended. Depression. Suicidal tendencies. Impulse control/compulsive behaviors; consider dose reduction or discontinuation if develops. Peptic ulcer. Glaucoma; monitor IOP. Withdrawal-emergent hyperpyrexia or confusion: avoid sudden discontinuation or rapid dose reduction. Pregnancy. Nursing mothers.

DHIVY Classification:

Dopa-decarboxylase inhibitor + dopamine precursor.

DHIVY Interactions:

See Contraindications. Concomitant dopamine-depleting agents (eg, reserpine, tetrabenazine) or other drugs known to deplete monoamine stores: not recommended. Antagonized by dopamine D2 receptor antagonists (eg, phenothiazines, butyrophenones, risperidone, metoclopramide), isoniazid, iron salts. Delayed absorption with high-protein diet, high-fat, high-calorie meals or excessive acidity. May cause false (+) urinary ketone test or false (–) urinary glucose (glucose oxidase) test.

Adverse Reactions:

Dyskinesias (eg, choreiform, dystonic), other involuntary movements, nausea; cardiovascular ischemic events, lab abnormalities.

Generic Drug Availability:


How Supplied: